{
  "docId": "019de514-6ff5-7310-813b-bef8d5f9ec91",
  "docSlug": "dbbeae38634aeeee4a36f290777f18f9",
  "documentTitle": "Vivani Medical | Mergers and Acquisitions Presentation Deck | 27 slides",
  "authorId": "vivani-medical",
  "authorName": "Vivani Medical",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 27,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a table to compare existing GLP-1 products with different administration methods, positioning the investigational candidate NPM-119 as a solution.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de514-6ff5-7310-813b-bef8d5f9ec91/14",
  "deckHref": "/decks/019de514-6ff5-7310-813b-bef8d5f9ec91",
  "deckJsonHref": "/decks/019de514-6ff5-7310-813b-bef8d5f9ec91.json",
  "deckAnchorHref": "/decks/019de514-6ff5-7310-813b-bef8d5f9ec91#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "list",
      "text": "Varying levels of adherence are associated with different health outcomes. Different health outcomes may not be attributable to drug substance alone. The American Diabetes Association (ADA) Standard of Care guidelines encourage treatment options that address adherence.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "32083b77-e75f-43ee-b8af-3b0dfacd0255",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "Drug Substance + Administration = Drug Product",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f8232a14-76b2-4b4a-801f-2428b11a6e39",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "* NPM-119 - investigational candidate, not approved in any market",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a8899bb1-3306-4168-bb2f-6917651c023f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.85,
        "w": 0.45,
        "x": 0.5,
        "y": 0.05
      },
      "kind": "table",
      "text": "Drug Substance, Administration, Drug Product columns with rows for exenatide, dulaglutide, semaglutide, and NPM-119.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cbd37737-6df0-4454-95cc-afa55af3be7d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Guaranteed adherence is expected to deliver improved health outcomes",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11bd946b-1109-44ba-b047-9abda297a8cd",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "causal-chain",
      "slug": null,
      "matchId": "8a99c9c6-08b3-4fcc-917a-91c5dbc26454",
      "evidence": "Drug Substance + Administration = Drug Product",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 14,
      "from": 13,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "b0a41e75-6ea8-44cb-86c0-1a8484735c00",
      "evidence": "The problem statement and solution presentation aim to highlight the consequences of inaction and the benefits of Vivani's technology.",
      "position": 0,
      "objective": "What are the consequences of not addressing the drug adherence challenge?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}